Anecortave Acetate
Treatment of subfoveal choroidal neovascularisation (CNV) due to exudative age-related macular degeneration (AMD) where the CNV is composed predominantly (>50%) of classic lesions.
Decision on record
- Meeting Nov 2006 Recommended Subfoveal choroidal neo- vascularisation (CNV)
Access path
- Mar 2006Not recommended
Inadequate evidence that anecortave is no worse than PDT with verteporfin in effectiveness and safety; pre-specified…
- Mar 2006Not recommended
inadequate evidence to support non-inferiority claim versus verteporfin; pre-specified non-inferiority criterion (7.0%)…
- ↻ resubmittedNov 2006Recommended · restricted
Comparator changed: photodynamic therapy with verteporfin → photodynamic therapy (PDT)…
- Nov 2006Recommended · restricted
Comparator changed: photodynamic therapy with verteporfin → photodynamic therapy (PDT)…
- PBS listing · Authority Required
Cost-effectiveness
The incremental cost per additional QALY gained from treatment with PDT with verteporfin versus anecortave acetate was estimated to be in the range $105,000 – $200,000. PSD · 2006
Decision context
PopulationPatients with subfoveal CNV due to exudative AMD with predominantly (>50%) classic lesions and baseline visual acuity equal to or better than 6/60 (20/200).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2006 | Recommended · restricted | photodynamic therapy (PDT) with verteporfin | $105k–200k | RCT |
| Nov 2006 | Recommended · restricted | photodynamic therapy (PDT) with verteporfin | $105k–200k | RCT |
| Mar 2006 | Not recommended | photodynamic therapy with verteporfin | — | RCT, Single-arm · QoL |
| Mar 2006 | Not recommended | photodynamic therapy with verteporfin | — | RCT |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to >50% classic lesions, baseline VA ≥6/60, and requires fluorescein angiography confirmation; TGA label only requires classic component presence.